Autopsy report · NCT04037462

Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapy

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“Low accrual”

The sponsor’s own words in the registry.

Life of this trial

Registered 1 year 11 months before it started.
Ran for about 1 year 8 months before it stopped.
2 participants enrolled.
Results were posted on the registry 1 year 4 months after it ended.

Vital statistics

Status: Terminated
Phase: Phase 1, Phase 2
Sponsor: VA Office of Research and Development
Sponsor type: US federal agency
Conditions: Non-Small Cell Lung Cancer; Immunotherapy
Interventions: Dexamthasone
Participants: 2
Sites: 1
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.